Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)

Poly-ADP ribose polymerase inhibitors (PARPi) have immunomodulatory properties, notably by activating the cGAS/STING innate immune pathway and by inducing PD-L1 expression. The Gustave Roussy-sponsored academic Phase 2 basket study ARIANES (EudraCT 2018-001744-62) evaluated the efficacy of the PARPi rucaparib (R) in combination with the anti-PD-L1 atezolizumab (A) in unselected, platinum-sensitive, or molecularly-selected pts. Here we report results from the platinum-sensitive mUC and unselected mCRPC cohorts.